Wordt geladen...
Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials
OBJECTIVE: Advanced therapy medicinal products (ATMPs) constitute a class of innovative products that encompasses gene therapy, somatic cell therapy, and tissue-engineered products (TEP). There is an increased investment of commercial and non-commercial sponsors in this field and a growing number of...
Bewaard in:
| Gepubliceerd in: | J Mark Access Health Policy |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Co-Action Publishing
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4973442/ https://ncbi.nlm.nih.gov/pubmed/27570614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3402/jmahp.v4.32232 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|